Arcus biosciences reports fourth quarter and full-year 2021 financial results and provides corporate update

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the fourth quarter and year ended december 31, 2021 and provided a corporate update on its six clinical-stage molecules targeting tigit, the adenosine axis (cd73 and dual a2a/a2b receptor), hif-2a and pd-1 across common cancers, including lung
RCUS Ratings Summary
RCUS Quant Ranking